SCHEMBL2069796

SCHEMBL2069796

COC(=O)c1cccc(N2CCCC(CN3C(=O)c4ccccc4C3=O)C2)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.49
HSD17B10 Q99714 2/20 0.49
ALDH1A1 P00352 6/20 0.47
HPGD P15428 2/20 0.46
PPARA Q07869 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
GAA P10253 1/20 0.43
ATM Q13315 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
GRM2 Q14416 1/20 0.42
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
PKM P14618 1/20 0.41
ALOX15 P16050 1/20 0.41
DPP4 P27487 1/20 0.41
POLB P06746 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2069141 0.83 KMT2A (0.52) HSD17B10ALDH1A1HPGDPPARAGAA
SCHEMBL2070213 0.82 BPTF (0.49) HSD17B10ALDH1A1HPGDPPARASMN1; SMN2
SCHEMBL2071216 0.81 CHRNB4 (0.48) HSD17B10ALDH1A1SMN1; SMN2KMT2AMAPT
SCHEMBL8323805 0.78 KMT2A (0.51) KMT2APOLB
SCHEMBL15630696 0.77 ALDH1A1 (0.50) HSD17B10ALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL15630772 0.76 DPP4 (0.51) HSD17B10ALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL2070008 0.76 DPP4 (0.51) HSD17B10ALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL2070351 0.75 NOTUM (0.56) HSD17B10ALDH1A1HPGDPPARAGAA
SCHEMBL3891135 0.75 DPP4 (0.42) HSD17B10KMT2ADPP4POLB
Hydrochloric Acid SCHEMBL28486757 0.74 BPTF (0.56) ALDH1A1HPGDPPARAGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
EP-1780210-A1 NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE Kyorin Pharmaceutical Co., Ltd. (JP) 2007-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative PPARA, PPARG, PPARD MAPK1 1425/4885HSD17B10 304/4885ALDH1A1 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.